Summary of WuXi XDC Cayman Inc. Conference Call Company and Industry Overview - **Company**: WuXi XDC Cayman Inc. - **Industry**: China Healthcare Key Points and Arguments 1. **MSCI Inclusion Impact**: Inclusion in the MSCI China All Share Index is expected to broaden the investor base, providing comfort to portfolio managers regarding stock tradeability and interest from generalist investors [5][1] 2. **Growth and Earnings Visibility**: WuXi XDC is noted for having the highest growth and earnings visibility within the WuXi family, with an expected earnings CAGR of over 30% from 2024 to 2028 [2][1] 3. **Competitive Position**: The company has a strong competitive moat and leading indicators, making it a top pick compared to its peers, WuXi Biologics and WuXi AppTec [2][1] 4. **Market Capitalization Growth**: From the beginning of 2025 to the end of July, WuXi XDC's market cap increased from US$4.7 billion to US$8.8 billion, representing an 87% growth, significantly outperforming the 35% growth of the healthcare sector [5][1] 5. **Financial Performance**: Preliminary results for the first half of 2025 exceeded expectations, and a doubling of formulation capacity is anticipated, indicating conservative guidance and a significant backlog addition [2][1] 6. **Valuation Metrics**: The company’s price target is set at HK$60.00, with a current price of HK$56.05, indicating a 7% upside potential. The market cap is approximately RMB 61.45 billion [3][1] 7. **Earnings Projections**: Projected EPS for the fiscal years ending in 2025, 2026, and 2027 are RMB 1.24, RMB 1.66, and RMB 2.17 respectively, with revenues expected to grow from RMB 4.05 billion in 2024 to RMB 9.66 billion in 2027 [3][1] 8. **Risks Identified**: Potential risks include a deceleration in biotech funding, missed sales expectations for late-stage projects, and lower-than-expected gross margin improvements from new facilities [8][1] Additional Important Information - **Analyst Ratings**: The stock is rated as "Overweight" with an attractive industry view, indicating a positive outlook for the company compared to its peers [3][1] - **Market Dynamics**: The inclusion in the MSCI index is expected to enhance liquidity, potentially shifting investment preferences towards WuXi XDC over its parent company [2][1] - **Long-term Growth Strategy**: The company is positioned for significant growth, supported by its development stage and market conditions, with a focus on expanding its capabilities and market presence [6][1]

Summary of WuXi XDC Cayman Inc. Conference Call Company Overview - **Company**: WuXi XDC Cayman Inc. - **Industry**: China Healthcare, specifically within the Contract Development and Manufacturing Organization (CDMO) sector - **Ticker**: 2268.HK Key Points Earnings and Growth - WuXi XDC has the highest earnings visibility within its CDMO coverage, with management guiding for over 30% earnings CAGR from 2024 to 2028 [3] - Preliminary earnings growth for 1H25 was over 60% YoY, attributed to strong demand, market share gains, and capacity scale-up [3] - The company reported "high/full" capacity utilization on its first two drug product lines (DP1 and DP2), indicating robust operational efficiency [3] Capacity Expansion - The newly GMP certified DP3 line in Wuxi city has an annual capacity of 7 million vials, doubling the total DP capacity to 15 million vials [8] - The DP3 line supports both clinical and commercial scale manufacturing, with high-speed filling capabilities of 300 vials per minute [8] - An upcoming facility in Singapore's Tuas Biomedical Park is projected to add another 8 million vials of capacity, enhancing the company's dual-sourcing strategy [3][8] Market Trends - The CDMO sector is experiencing an up-cycle, with a re-acceleration of investments noted in late 2024 and early 2025 following a post-COVID pullback [4] - Global leaders in the CDMO space, including WuXi group companies, have reported consensus beats and/or raised guidance for the year, with the US market being a significant driver of outperformance [4] Financial Metrics - Current market cap is approximately RMB 63,366.3 million, with an enterprise value of RMB 60,158.2 million [6] - Revenue projections for the next few years are as follows: - 2024: RMB 4,052 million - 2025: RMB 5,542 million - 2026: RMB 7,401 million - 2027: RMB 9,659 million [6] - EPS estimates are projected to grow from RMB 0.91 in 2024 to RMB 2.17 in 2027 [6] Risks and Opportunities - **Upside Risks**: - Increasing orders from all stages of drug development - Successful launch of blockbuster products - Accelerated gross margin improvement from the new Singapore facility [11] - **Downside Risks**: - Potential deceleration in biotech funding and pipeline progression - Late-stage and commercial contracts missing sales expectations - Lower-than-expected gross margin improvement from new facilities [11] Valuation - The price target for WuXi XDC is set at HK$60.00, indicating a 4% upside from the current price of HK$57.55 [6] Conclusion WuXi XDC Cayman Inc. is positioned for significant growth within the CDMO sector, supported by strong earnings visibility, capacity expansion, and favorable market trends. However, potential risks related to market dynamics and operational performance should be monitored closely.

Investment Ratings - The report assigns an Overweight (OW) rating to China Resources Land, Sony Group, and Eternal [1][2][17]. Core Insights - China Resources Land is viewed as a transformation story with strong recurring profits justifying a re-rating, leading to its designation as a Top Pick [1]. - Sony Group's Game & Network Services segment is expected to continue driving growth, with a recovery anticipated in television programming production, prompting a price target increase and reiteration as a Top Pick [2]. - Eternal is recognized for its market leadership, superior cost structure, and stronger balance sheet compared to peers, with a favorable risk-reward profile, reaffirming its status as a Top Pick [2]. Summary by Sections Performance Summary - As of June 3, 2025, there are 1,353 ideas with a cumulative outperformance of 6,831 basis points against local benchmarks [3]. - The average holding period total return is 3.0%, while the average 12-month total return is -1.9% [3]. - The hit ratio for positive returns stands at 53% [3]. Market Insights - The report highlights that Hong Kong and China account for the most ideas in the region, followed by Japan [25]. - India generated the best holding period relative return at 5.1%, while Korea had the lowest at 1.9% [25]. Valuation Methodology - For China Resources Land, the estimated NAV is HK$55.43 per share, with a 30% discount applied based on a developers' scorecard [37]. - Sony Group's price target is based on a fair EV/EBITDA of 11.6x on FY3/27 earnings estimates [38]. - Eternal's valuation is based on EV/adjusted EBITDA, with a weighted approach reflecting expectations of continued positive surprises [39].

Investment Rating - The report maintains an Equal-weight (EW) stance on MSCI China within the global EM/APXJ framework [9]. Core Insights - The report anticipates higher near-term market volatility due to the US imposing additional tariffs on China, raising the total tariff rate to up to 65% [2][4]. - The A-share market is viewed as better positioned for hedging and diversification compared to the offshore market, as A-share investors are less sensitive to tariff changes [3]. - The direct impact on earnings from the tariffs is expected to be smaller than the overall drag on macroeconomic growth, with the MSCI China universe generating only 13% of its total revenue from markets outside China, and less than 3% from the US [7]. Summary by Sections Market Volatility - The report highlights that the recent tariff hikes could lead to elevated market volatility as the market adjusts to the potential economic impacts [2][4]. A-Share Market Positioning - The A-share market is recommended for investors seeking stability, as it has shown lower correlation with global markets and less volatility compared to offshore markets [3]. Earnings Impact - The report suggests that the overall drag on equity market earnings will be less severe than the impact on macro growth, primarily due to the limited revenue exposure of listed Chinese companies to the US market [7]. Companies with High US Revenue Exposure - A list of 30 companies with the highest revenue exposure to the US market is provided, indicating potential negative impacts on these companies in the near term [8]. Key Indicators to Monitor - The report advises monitoring the USDCNY exchange rate, signs of US-China negotiations, and any significant policy easing measures to stabilize domestic growth [9].

Summary of WuXi's FY24 Preview and Outlook Industry Overview - **Industry**: China Healthcare, specifically focusing on the CRO/CDMO (Contract Research Organization/Contract Development and Manufacturing Organization) sector - **Key Players**: WuXi AppTec, WuXi Biologics, WuXi XDC Core Insights and Arguments 1. **Valuation Recovery**: Current valuations do not adequately reflect positive trends such as early-stage demand recovery, bottoming prices, and growth in new modalities. WuXi's results and backlog growth are critical indicators of an industry uptrend [1][2][20] 2. **Biosecure Act Impact**: The Biosecure Act's year-long debate has concluded, stabilizing the average FY2 P/E for the CRO/CDMO segment at 20x, close to pre-Biosecure levels. Structural factors are becoming more favorable, including a resurgence in drug R&D demand and increased capacity utilization [2][3][20] 3. **Geopolitical Risks**: WuXi's market share stability is questioned amid geopolitical risks, including tariffs and potential future iterations of the Biosecure Act. However, the year-long debate has allowed for a more rational assessment of WuXi's role in the global drug supply chain [3][19] 4. **Stock Preferences**: WuXi XDC is favored due to its lower geopolitical exposure and strong market share in outsourced bioconjugates. WuXi AppTec is well-positioned to benefit from GLP-1 outsourcing demand, while WuXi Bio has secured a significant number of new projects despite regulatory challenges [4][26][34] Financial Performance and Projections 1. **Earnings Guidance**: WuXi AppTec is projected to see modest revenue growth in 2025, with a backlog growth likely to surprise positively. WuXi Biologics is expected to maintain in-line performance, while WuXi XDC anticipates significant upside due to backlog growth and capital expenditure announcements [9][24] 2. **Revenue Growth**: WuXi AppTec's revenue is expected to decline slightly in 2024 but rebound in 2025, while WuXi Bio anticipates 5-10% revenue growth. WuXi XDC is projected to achieve over 85% revenue growth in 2024 [24][32][34] 3. **Valuation Metrics**: WuXi AppTec is trading at a P/E of 15x-16x for 2025, while WuXi Bio is at 21x. WuXi XDC's valuation is at 30x, which is considered undemanding given its projected earnings growth [28][33][37] Emerging Trends and Opportunities 1. **New Modalities**: The development of emerging modalities such as ADCs (Antibody-Drug Conjugates) and GLP-1 peptides is driving demand. WuXi's capabilities in these areas position it well for future growth [2][34] 2. **Global Expansion**: WuXi is focusing on overseas capacity expansion to mitigate geopolitical risks and enhance profitability. The company aims for a balanced revenue contribution between China and international markets by 2030 [3][31][19] 3. **Market Leadership**: WuXi AppTec's leadership in small molecule chemical synthesis is reinforced by its ability to adapt to complex demands and competitive pricing, while WuXi Bio is leveraging its CRDMO model to manage risks in biologics outsourcing [26][29] Important Considerations 1. **Investor Sentiment**: Despite positive earnings growth prospects, investor concerns remain regarding the potential re-emergence of the Biosecure Act and its implications for stock performance [18][19] 2. **Profitability and Capex**: The level of profitability from overseas facilities and the capital expenditure plans are crucial factors to monitor as WuXi navigates its global dual-sourcing strategy [19][20] This comprehensive analysis highlights the potential for growth within WuXi and the broader CRO/CDMO sector, while also acknowledging the challenges posed by geopolitical factors and regulatory uncertainties.